PR

2025114

PR Notice Regarding Completion of 30-Day Review for Clinical Trial Notification for Phase I/II Study of Cardiac Remuscularization Therapy HS-005 (Catheter Administration) Targeting Severe Heart Failure

2025911

PR Notice Regarding the New Partner for Delivery Catheter System for Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids

202523

PR Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart Failure

2024101

PR Notice Concerning Positive Recommendation from Safety Monitoring Committee for Continuing High-dose Arm in HS-001 Clinical Trial (LAPiS Study)

2024730

PR Heartseed Announces Positive Recommendation from Safety Monitoring Committee for Dose Escalation in Phase 1/2 Clinical Trial Dosed With HS-001

2024730

PR Notice of Listing on the Growth Market of the Tokyo Stock Exchange

2024626

PR Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange

202452

PR Heartseed.'s CFO, Mutsuki Takano, Named "Most Innovative CFO from Asia to Watch in 2024" by CXO Magazine

202449

PR Prof. Massimiliano Gnecchi, Renowned Translational Cardiology Expert, Delivers Lecture at Heartseed.

2024325

PR Heartseed CEO Keiichi Fukuda Wins Japanese Society for Regenerative Medicine "Achievement Award"

1 2 3 4